Skip to content
Open access

Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer

Oct 2026 · JAMA Network Open · Vol 9 · 0 citations · 19 references
Medicine

Abstract

This economic evaluation assesses the health economic value, for a US Medicare payer, of adopting perioperative enfortumab vedotin plus pembrolizumab for treatment of cisplatin-ineligible patients with muscle-invasive bladder cancer.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.